Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single- and Multiple-Ascending Dose Study of Intrathecal LY3962681 in Healthy Volunteers and Patients With Parkinson's Disease
jRCT2031240316Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LY3962681 in Parkinson's disease (PD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Incidence of Serious Adverse Events (SAEs), Incidence of Treatment Emergent Adverse Events (TEAEs) and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
LY3962681
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2031240316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240316.